Royalty Report: Drugs, Cancer, Therapeutic – Collection: 286016

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 9

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Disease
  • Weight Loss
  • Food
  • Medical
  • Diagnostic
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 286016

License Grant
Licensor of Israel hereby grants to Licensee a worldwide license to practice under the Patent Rights, and to make, have made, use, lease, and/or sell the Licensed Products in the Licensee Field and to practice the Licensed Processes in the Licensee Field, said license being perpetual unless sooner terminated as hereinafter provided and subject to the payment of royalties as hereinafter provided,  and said license to include the right to sublicense in the Licensee Field and to be exclusive to Licensee in the Licensee Field.
License Property
Patent Rights shall mean Israeli Patent Applications Nos. 83389 and 87072, filed July 30, 1987 and July 11, 1988, respectively; and any applications claiming priority or benefit directly or indirectly from either or both of them, including any continuations, continuations-in-part, and divisionals thereof; and any patents issuing from any of the foregoing, including any reissues, reexaminations, and extensions thereof; as set forth.

US Patent #5,200,553 – Biologically active carboxylic acid esters

Licensed Product(s) shall mean: Any product which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the product is made, used, leased, or sold; Any product which is manufactured by using a process which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the process is used; Any product which is used according to a method which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the method is used.

Licensed Process(es) shall mean any process or method, which is covered, in whole or in part, by a valid and unexpired claim contained in the Patent Rights in the country in which the process or method is used.

Field of Use
Licensee Field shall mean: (a) with respect to butylidene dibutyrate (sometimes referred to as AN-10), non-topical applications for oncologic disorders; and (b) with respect to all other products within the Patent Rights, all indications and routes of administration except (i) the treatment of (-hemoglobinopathies ((-globin disorders) and (ii) topical applications other than oncologic disorders. The term oncologic disorders shall not include chemotherapy-or radiotherapy-induced alopecia.

IPSCIO Record ID: 169272

License Grant
In this agreement where Licensee is the principal stockholder of Licensor, Licensor shall grant to Licensee a worldwide sublicense to practice under the Patent Rights , and to make, have made, use, lease and/or sell the Licensed Products in the Licensee Field and to practice the Licensed Processes in the Licensee Field, said sublicense to include the right to subsublicense in the Licensee Field and to be exclusive to Licensee in the Licensee Field.
License Property
These Patent Rights are licensed to the Licensor pursuant to the terms of a License Agreement dated as of October 31, 1992.

Licensee at its own expense and utilizing patent counsel of its choice shall have the sole right and responsibility for the prosecution and maintenance of the Nudelman Patent, provided that Licensee shall not take any action with respect to the Nudelman Patent that could result in any diminution of rights relating to the composition of matter claims relating to AN10.  Licensor shall have the sole right and responsibility for the prosecution and  maintenance of the Hemoglobinopathies Patent.

Hemoglobinopathies Patent shall mean issued U.S. Patent No. 5,569,675 and any related foreign patent applications or patents, including any continuations, continuations-in-part, divisional, reissues, reexaminations or extensions thereof.

Nudelman Patent shall mean issued U.S. Patent No. 5,200,553 and any related foreign patent applications or patents, including any continuations, continuations-in-part, divisional, reissues, reexaminations or extensions thereof.

AN 10 shall mean butylidene dibutyrate.

Field of Use
This agreement pertains to the drug industry relating to the field (a) with respect to all compounds except AN  10, all indications except (i) those covered by the Hemoglobinopathies Patent and (ii) topical applications (other than oncologic disorders) and (b) with respect to AN 10, non-topical applications for oncologic disorders.

IPSCIO Record ID: 230821

License Grant
Licensor, a not-for-profit pediatric health care and biomedical research services holding company,  hereby grants to Licensee an exclusive worldwide right and license in the Non-Thalidomide Field, to make, have made, use, lease, and sell the Licensed Products and to practice the Licensed Processes under the Patent Rights. Licensor shall retain a royalty-free, nonexclusive, irrevocable license to practice the Patent Rights for research purposes only.
License Property
A Licensed Product shall mean any product or part thereof which does not contain Thalidomide, alone or in combination, and which:

    *     Is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Product is made, used, or sold;

    *     Is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Process is used or in which the Licensed Product is used or sold.

A Licensed Process shall mean any process with application solely in the Non-Thalidomide Field and which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights.

Field of Use
Non-Thalidomide Field shall mean the use of any compound other than Thalidomide, alone or in combination, in humans or animals, including without limitation any and all diagnostic, prophylactic, therapeutic, and research and development uses.

Thalidomide may have use in treating diseases fed by the growth of tiny blood vessels – a growth process known as angiogenesis.

Licensee licensed the use of Thalidomide for cancer and other antiangiogenic mediated diseases from Licensor, and conducted four Phase II clinical trials and secured two orphan drug indications for the use of thalidomide in certain cancers.

IPSCIO Record ID: 273410

License Grant
Licensor hereby grants to Licensee and Licensee hereby accepts from Licensee, subject to the terms and conditions of this agreement, the exclusive right and sublicenseable license for the field of use in the territory to practice under the Licensor Patent Rights to develop, make, have made, import, use, lease, offer for sale, sell, and distribute Licensor Licensed Products for the field of use in the territory only, to develop, make, have made, import, use, lease, offer for sale, sell, and distribute Licensor Licensed Processes in/for the field of use in the territory, and/or to develop, make, have made, perform, provide, import, use, lease, offer for sale, sell, and distribute Licensor Licensed Services in the field of use in the territory only until the end of the term for which the Licensor Patent Rights are granted unless this agreement shall be sooner terminated according to the terms hereinafter provided.
License Property
Patent Rights shall mean the patents, patent applications listed below, together with all divisions, continuations, continuations-in-part re-examinations, reissues, substitutions, or extensions thereof and patents issuing therefrom in the United States and non-U.S. jurisdictions. Notwithstanding the foregoing or anything else to the contrary in this agreement:
US Patent Application SN 10/440,404, entitled, 'Method for Treating Obesity' and filed May 19, 2003. (Atising from Licensor Office of Science and Technology File #2081)
PCT Patent Application PCT/US03/15703, entitled, 'Method of Treating Obesity and filed May 19, 2003. (Arising from Licensor Office of Science and Technology File #2081)
US Provisional Patent Application SN 60/535,799, entitled, 'Method of Reducing Weight Gain Risk Associated with Antidepressant Therapy' and filed January 13, 2004. (Arising from Licensor Office of Science and Technology File# 2308)
US Provisional Patent Application SN 60/535,800, entitled Method of Reducing Weight Gain Risk Associated with Antipsychotic Therapy' and filed January 13, 2004. (Arising from Licensor Office of Science and Technology File #2294)

Licensed Product shall mean any product or part thereof which:
(a)
is covered in whole or in part by any valid claim contained in the Licensor Patent Rights in the country in which any such product or part thereof is made, used or sold; and/or
(b)
is manufactured by using a process or is employed to practice a process which is covered in whole or in part by a valid claim contained in the Licensor Patent Rights in the country in which any Licensor Licensed Process is used or in which such product or part thereof is used or sold; and/or
c)
in its intended use, practices, incorporates, or otherwise utilizes, in whole, or in part, a valid claim contained in the Licensor Patent Rights in the country in which any such product or part thereof is made, used, or sold.

Licensed Process shall mean any process which is covered in whole or in part by a valid claim contained in the Licensor Patent Rights.

Licensed Service shall mean any service provided by Licensee (and/or sublicensees, as the case may be) to a third party which utilizes Licensor Licensed Products and/or Licensor Licensed Processes.

Field of Use
The Gadde patent is a U.S. patent covering the composition of our Empatic product candidate and methods for using Empatic to treat obesity and reduce the risk of hypertension, diabetes or dyslipidemia.

IPSCIO Record ID: 282830

License Grant
University hereby grants to Licensee the exclusive, worldwide right and license to make, have made, use and sell Defined Products and Licensed Processes until, as to any particular United States or Foreign patent which is or becomes part of the Patent Rights, the expiration of such patent (including any extension of the expiration date by the applicable governmental authority), unless sooner terminated as hereinafter provided.
License Property
Defined Product shall mean any Licensed Product, or any product produced using any Licensed Process or containing a Licensed Product. University and Licensee assume that a product claim will be allowed by the United States Patent and Trademark Office and therefore that United States Patent 5,019,408 will reissue with a product claim therein. Licensee agrees that any manufacture, use, or sale of the Raztek Product will infringe the aforesaid patent as reissued with a product claim contained therein and be a Defined Product hereunder.

Licensed Product shall mean any product which (a) is covered by a valid and unexpired claim contained in a Patent Rights Patent in the country in which such Licensed Product is made, used or sold; or (b) is covered by a claim which is contained in a pending Patent Rights Patent Application in the country in which such Licensed Product is made, used or sold.

Patent Rights shall mean (a) United States Patent 4,808,425, issued February 28, 1989, entitled 'Method for the Ultrapasteurization of Liquid Whole Egg Products'; (b) United States Patent 4,957,759, issued September 18, 1990, entitled 'Ultra-Pasteurization of Liquid Whole Egg Products'; (c) United States Patent 4,994,291 issued February 19, 1991 entitled 'Method for Pasteurizing Liquid Whole Egg Products'; (d) United States Patent 5,019,408 issued May 28, 1991, entitled 'Method for Pasteurizing Liquid Whole Egg Products'; and (e) United States Patent 4.957,760 issued September 18, 1990 entitled 'Ultrapasteurization of Liquid Whole Egg Products by Direct Heat' and any continuations, divisions, reissues, reexaminations and extensions thereof (collectively 'Patent Rights Patents'); and all existing and later-filed U.S. or foreign patent applications corresponding to or claiming priority benefit of any of the foregoing, and any continuations, divisions, reissues, reexaminations and extensions thereof including without limitation the currently pending reissue application of United States Patent 5,019,408 which includes the product claim referred to in Section 1.4 (collectively 'Patent Rights Patent Applications').

Licensed Process shall mean any process which (a) is covered by a valid and unexpired claim contained in a Patent Rights Patent in the country in which such Licensed Process is used or practiced; or (b) is covered by a claim which is contained in a pending Patent Rights Patent Application in the country in which such Licensed Process is used or practiced.

Field of Use
This agreement pertains to the food industry relating to ultra pasteurization of liquid whole egg products.

IPSCIO Record ID: 203485

License Grant
The University grants the worldwide right and license to make, have made, use, lease and sell the Licensed Products, and to practice the Licensed Processes.

Licensor agrees that it shall not grant any other license to make, have made, use, lease and sell Licensed Products or to utilize Licensed Processes in the Research or In Vitro Diagnostics fields and in the In Vivo Diagnostics field and the Therapeutics field of use during the period.

At the end of the exclusivity period, the Licensee may extend the exclusivity or the rights will change to non-exclusive for the remainder of the term of the agreement.

Licensor agrees that its grant to Licensee to use of the Tangible Property for commercial purposes shall be exclusive in perpetuity unless this Agreement is terminated prior to the last to expire of the Patent Rights.

License Property
Licensor is the owner of certain Patent Rights relating to Method For Determining Tissue Of Origin And Degree Of Malignancy Of Tumor Cells.  The patent applications as of this agreement, include but are not limited to, A method for determining the tissue of origin of a cell and degree of malignancy, and, The method wherein tho nuclear matrix proteins are isolated, and, The method wherein the cytoskeleton proteins are solubilized, and, A method for detecting tumor antigens in a body fluid comprising reacting labeled monoclonal antibodies to nuclear matrix proteins of known origin and degree of malignancy with the body fluid to be analyzed .

The Tangible Property shall mean any or all of the hybridorna cell lines from the Licensors laboratory with the designation(s) MCF-7 Bl through B9.

A Licensed Product shall mean any product or part thereof which:
(a)  is covered in whole or in part by a pending claim contained in a Patent Rights Patent Application in the country in which any Licensed Product is made, used or sold; or, a valid and unexpired claim contained in a Patent Rights Patent in the country in which any Licensed Product is made, used or sold; or
(b)  is manufactured using a process which is covered in whole or in part by a pending claim contained in a Patent Rights Patent Application in the country in which any Licensed Process is used, or, a valid or unexpired claim contained in a Patent Rights Patent in the country in which any Licensed Process is used; or,
(c)  is developed or manufactured using the Tangible Property.

A Licensed Process shall mean any process for making Licensed Products which is covered in whole or in part by:
(a)  a pending claim contained in a Patent Rights Patent Application; or
(b)  a valid and unexpired claim contained in a Patent Rights Patent; or which
(c)  uses the Tangible Property.

Field of Use
The fields of use are Research or In Vitro Diagnostics fields and in the In Vivo Diagnostics field and the Therapeutics field.

The Licensee develops, produces and distributes products for the diagnosis and potential treatment of cancer based on its proprietary nuclear matrix protein technology.

IPSCIO Record ID: 273408

License Grant
In consideration of the premises and the mutual agreements hereinafter set forth, the parties hereby agree to amend the following: The meaning for the term 'net sales'; the sublicensing rights; royalty and milestone payments relating to the Licensed Products, Processes and Services.
License Property
Patent Rights shall mean the patents, patent applications listed below, together with all divisions, continuations, continuations-in-part re-examinations, reissues, substitutions, or extensions thereof and patents issuing therefrom in the United States and non-U.S. jurisdictions. Notwithstanding the foregoing or anything else to the contrary in this agreement:

US Patent Application SN 10/440,404, entitled, 'Method for Treating Obesity' and filed May 19, 2003. (Atising from Licensor Office of Science and Technology File #2081)
PCT Patent Application PCT/US03/15703, entitled, 'Method of Treating Obesity and filed May 19, 2003. (Arising from Licensor Office of Science and Technology File #2081) US Provisional Patent Application SN 60/535,799, entitled, 'Method of Reducing Weight Gain Risk Associated with Antidepressant Therapy' and filed January 13, 2004. (Arising from Licensor Office of Science and Technology File# 2308)
US Provisional Patent Application SN 60/535,800, entitled Method of Reducing Weight Gain Risk Associated with Antipsychotic Therapy' and filed January 13, 2004. (Arising from Licensor Office of Science and Technology File #2294)

Licensed Product shall mean any product or part thereof which: (a)
is covered in whole or in part by any valid claim contained in the Licensor Patent Rights in the country in which any such product or part thereof is made, used or sold; and/or (b) is manufactured by using a process or is employed to practice a process which is covered in whole or in part by a valid claim contained in the Licensor Patent Rights in the country in which any Licensor Licensed Process is used or in which such product or part thereof is used or sold; and/or c)
in its intended use, practices, incorporates, or otherwise utilizes, in whole, or in part, a valid claim contained in the Licensor Patent Rights in the country in which any such product or part thereof is made, used, or sold.

Licensed Process shall mean any process which is covered in whole or in part by a valid claim contained in the Licensor Patent Rights.

Licensed Service shall mean any service provided by Licensee (and/or sublicensees, as the case may be) to a third party which utilizes Licensor Licensed Products and/or Licensor Licensed Processes.

Field of Use
The Gadde patent is a U.S. patent covering the composition of our Empatic product candidate and methods for using Empatic to treat obesity and reduce the risk of hypertension, diabetes or dyslipidemia.

IPSCIO Record ID: 230759

License Grant
The University grants the non-exclusive right and license to make, have made, use, lease and sell the Licensed Products, and to practice the Licensed Processes in the Territory for the Fields of Use to the end of the term for which the Patent Rights are granted unless sooner terminated according to the terms hereof.
License Property
The patent is for AAV Transduction Vectors.

A Licensed Process is any process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights; or, Patent Rights; or, is derived from Patent Rights or know-how, and related to or described in is sold, manufactured or used in any country under this Agreement.

A Licensed Product shall mean any product or part thereof which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Products are made, used or sold; or,  is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Process is used or in which such product or part thereof is used or sold; or,
is derived from Patent Rights or know-how, and related to or described in Patent Rights.

Field of Use
The Fields of Use shall mean:
(a) Human [blood] disorders, [metabolic and congenital]. This field includes human [hematological] diseases that arise due to the absence, over-expression or altered expression of proteins normally (present in blood]. The primary site and location of these proteins is [blood]. Specifically included are human [hemoglobinopathies (i. e. Sickle Cell Anemia and Thalassemia)] and human disorders of the [coagulation metabolism (i.e., Hemophilia A (factor VIII), Von Willebrands Disease (factor VIII) and Hemophilia B (factor IX))]. Specifically excluded are human [neoplasias of the lymphoreticular system (lymphomas, reticuloendothelioses, or plasma cell dyscrasias)].

(b) Human [malignant neoplastic] diseases. This field includes all forms of human (cancer, including but not limited to skin cancers and all solid tumors]. This field also includes all forms of human [cancers of the hematopoietic tissues (the leukemias), Hodgkins Disease and Non-Hodgkins Lymphoma].

c) relating to a syndrome (AIDS) characterized by opportunistic infections occuring as a result of profound
deficiency of the helper – T4 lymphocytes (CD4 lymphocytes). At any time during the life of this Agreement the definition of AIDs shall be that definition currently in use by the Centers for Disease Control, Atlanta, Georgia].

(d) All human [infectious diseases other than HIV]. This Field includes: [human viral diseases (besides HIVs, human bacterial, yeast and other microorganism based diseases, and all other human infectious diseases.

IPSCIO Record ID: 279311

License Grant
University grant to Licensee, and Licensee hereby accepts, a royalty-bearing, exclusive license under Licensed Subject Matter to make, have made, manufacture, have manufactured, use, import, offer to sell, sell and/or have sold products within Licensed Territory for use within Licensed Field. This grant is subject herein below, the payment by Licensee to University of all consideration as provided herein, and is further subject to the following rights retained by University to:
(a) publish the general scientific findings from research related to Licensed Subject Matter, subject to the terms of Article XI-Confidential Information and Publication; and
(b) use Licensed Subject matter solely for its own internal, non-commercial research, teaching, and other educationally-related purposes; and
(c) request that the Licensee transfer Licensed Subject Matter to academic or research institutions for non-commercial research use or for purposes of collaboration upon terms reasonably acceptable to the Licensee and such third party; provided, however, that Licensee will not unreasonably withhold consent to University’s use of the Licensed Subject Matter in collaborations between University, and/or the National Cancer Institute (NCI).
License Property
Licensed Subject Matter means Patent Rights, Improvements and Technology Rights within Licensed Field.

Patent Rights means University’s rights in information or discoveries described in invention disclosures below or in the subsequent reductions to practice of such information or discoveries (so long as such subsequent reductions to practice are not obligated to a third party), or claimed in any patents, and/or patent applications, whether domestic or foreign, based on such invention disclosures and such reductions to practice (that are not obligated to a third party) and all domestic and foreign divisionals, continuations, continuations-in-part, reissues, reexaminations or extensions thereof, including any foreign counterparts thereto and any letters patent that issue thereon, including but not limited to: (a) Provisional Application entitled, “Compounds and Methods for the Treatment of Cancer” filed July 16, 2004; (b) U.S. Application Serial Number 60/346,492 filed January 7, 2002; (c) WO 2003/057012 filed January 7, 2003; (d) U.S. Application Serial Number 10/337,969 filed January 7, 2003; and (e) national stage filings for MDA01-063 in Europe, Japan, Canada and Australia.

MDA01-063 “New Organic Arsenic Derivatives as a Treatment for Cancer,” Srdan Verstovsek, M.D., Ph.D., Ralph A. Zingaro Ph.D., Emil J. Freireich, M.D., Hatice Duzkale, M.D., Hagop M. Kantarjian, M.D.

MDA04-076 “Arsenic-Lipid Derivatives as a Treatment for Cancer,” Srdan Verstovsek, M.D., Ph.D., Ralph A. Zingaro Ph.D., Hagop M. Kantarjian, M.D., M. Gao

Licensed Products means any product or service that is covered in whole or in part by a valid claim contained in the Patent Rights in the country in which the product is made, used, leased or sold.

Field of Use
Patent applications and related improvements and know-how) are for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes ZIO-101.

ZIO-101 is an organic arsenic compound covered by an issued U.S. patent and applications internationally. A form of commercially available inorganic arsenic (arsenic trioxide (Trisenox®) or ATO) has been approved for the treatment of acute promyelocytic leukemia (APL), a precancerous condition, and is on the compendia listing for the therapy of multiple myeloma as well as having been studied for the treatment of various other cancers.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.